Cedars-Sinai Heart Institute is currently conducting the following Hypertrophic Heart Disease clinical trials:
Long-term Outcomes of Percutaneous Alcohol Septal Ablation for Patients with Hypertrophic Cardiomyopathy
Principal Investigator: Raj Makkar, MD
IRB Approval Number: 9819
Contact: Michelle Domingo (310) 423-3875
Status: Data Analysis
Summary: The treatment of hypertrophic obstructive cardiomyopathy (HOCM) with alcohol septal ablation (ASA) has received increasing interest. However, there is a paucity of data on the long-term outcome of this treatment for patients who are symptomatic with this condition. Therefore, the main objective of this study is to evaluate the long-term outcomes of patients who underwent alcohol septal ablation at Cedars-Sinai Medical Center for hypertrophic obstructive cardiomyopathy.